EGFR and neoplasm: While the correlation of ctDNA and efficacy of EGFR‐TKI has been extensively investigated,21 this work presents one of the most comprehensive ctDNA genomic analyses of tumour evolution during osimertinib treatment, which is a third‐generation EGFR‐TKI.